Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;29(10):2400109.
doi: 10.2807/1560-7917.ES.2024.29.10.2400109.

Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024

Anne J Huiberts  1 , Christina E Hoeve  1 , Brechje de Gier  1 , Jeroen Cremer  1 , Bas van der Veer  1 , Hester E de Melker  1 , Janneke Hhm van de Wijgert  1   2 , Susan van den Hof  1 , Dirk Eggink  1   3 , Mirjam J Knol  1   3
Affiliations

Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024

Anne J Huiberts et al. Euro Surveill. 2024 Mar.

Abstract

We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23-55) in 18-59-year-olds and 50% (95% CI: 44-56) in 60-85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2-6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8-2.6).

Keywords: COVID-19; SARS-CoV-2; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
14-day moving average of the number of reported infections per 100,000 participants, by infection history and age group, the Netherlands, 9 October 2023–9 January 2024 (n = 23,895)
Figure 2
Figure 2
Vaccine effectivenessa of XBB.1.5 vaccine against SARS-CoV-2 Omicron infection among participants vaccinated with primary series and at least one booster and eligible for XBB.1.5 vaccination, stratified by age group, the Netherlands, 9 October 2023–9 January 2024 (n =23,895)
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention (CDC). COVID-19 activity increases as prevalence of JN.1 variant continues to rise. Atlanta: CDC; 2024. Available from: https://www.cdc.gov/respiratory-viruses/whats-new/JN.1-update-2024-01-05...
    1. Looi M-K. Covid-19: WHO adds JN.1 as new variant of interest. BMJ. 2023;383:2975. 10.1136/bmj.p2975 - DOI - PubMed
    1. Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, Hinay AA Jr, et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. [PREPRINT]. bioRxiv 2023:2023.12.08.570782 10.1101/2023.12.08.570782 - DOI - PubMed
    1. Andeweg SP, de Gier B, Eggink D, van den Ende C, van Maarseveen N, Ali L, et al. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. Nat Commun. 2022;13(1):4738. 10.1038/s41467-022-31838-8 - DOI - PMC - PubMed
    1. Rector A, Bloemen M, Schiettekatte G, Maes P, Van Ranst M, Wollants E. Sequencing directly from antigen-detection rapid diagnostic tests in Belgium, 2022: a gamechanger in genomic surveillance? Euro Surveill. 2023;28(9):2200618. 10.2807/1560-7917.ES.2023.28.9.2200618 - DOI - PMC - PubMed